Vaxxinity published data from an early-stage clinical trial showing that its investigative immunotherapy, UB-312, could improve movement in Parkinson’s disease and protect against pathological alpha-synuclein.
#parkinsons#biospace
https://t.co/mbE1BCb2AA
Check out our executive chairman @NotLouReese on Cheddar News Friday: Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market.
https://t.co/fUffrh9R3N
Vaxxinity Inc. will work with the University of Central Florida in Orlando to develop special new vaccines for astronauts that aim to prevent a common problem created during space exploration. Click for the details. https://t.co/hj80lIVl3O
Could space travel research deliver a frailty vaccine?
@vaxxinity and UCF collaborate on muscle and bone wasting immunotherapies to benefit both space exploration and human longevity.
@NotLouReese#longevity#space#research#vaccine
https://t.co/LfxhdQL8SR
Meet our Hidden Hero Rob Townley who work with some of our most complex and high risk projects at @Maersk👊Learn more about how Rob helps bring our #purpose to life⭐
👉Watch the full video: https://t.co/RNsWouAHwx
#Maersk#HiddenHero#alltheway#Career
Jean-Cosme Dodart (@vaxxinity) discussed recently published trial findings on a novel vaccine that targets Alzheimer's disease and triggers the production of antibodies against toxic amyloid-ß peptides.
Watch here 👇 https://t.co/1vlSxYqoRN
Treatment with an investigational anti-#amyloid therapeutic for adults with mild #AD was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a @Vaxxinity study published in @eBioMedicine. https://t.co/CqPkdxsHV6
Thought leader @DrJeffCummings sums up our latest publication in The Lancet’s @eBioMedicine about UB-311, the active vaccine candidate targeting beta-amyloid.
https://t.co/7DBkMUYJJm
Did you miss last week's fireside chat on vaccines for #dementia?
If so, you can find the inspiring & informative 30-minute conversation with ADI's @WeidnerWendy, @AC_Immune_SA's Andrea Pfeifer & Mei Mei Hu of @vaxxinity, on our YouTube channel. https://t.co/Smn6LvoTS9